Open an account

Hyperfine

HYPR · NASDAQ

$0.774−$0.0032 (−0.41%)TodayMarket closed ·
Prev close $0.7772

About HYPR

Hyperfine, Inc. is a medical device development company, which engages in providing imaging and monitoring through magnetic resonance imaging to revolutionize healthcare for people. The company is headquartered in Guilford, Connecticut and currently employs 102 full-time employees. The company went IPO on 2021-01-27. The firm is engaged in providing patient care globally through artificial intelligence (AI)-powered portable ultra-low-field (ULF) magnetic resonance (MR) brain imaging. Its Swoop Portable MR Imaging System (Swoop system) produces images at a lower magnetic field strength than conventional magnetic resonance imaging (MRI) scanners. Its Swoop system is designed to transform brain MR for the patient, the clinician and the provider, enabling a highly differentiated experience for patients, timely imaging for clinicians, and favorable economics for hospital administrators. The Swoop system is a portable ULF MRI device for producing images that display the internal structures of the head where full diagnostic examination is not clinically practical. The Swoop system is FDA-cleared for brain imaging of patients of all ages. The Swoop system is commercially available in a select number of international markets.

Employees
102
Headquarters
Guilford, Connecticut
Listed
Jan 27, 2021
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
hyperfinemri.com

HYPR key statistics

Market cap
82.08M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.26M
Volume
274.25K
Open price
$0.76
High today
$0.7771
Low today
$0.7501
52 Week high
$1.94
52 Week low
$0.74

Hyperfine (HYPR) at a glance

Hyperfine (HYPR) last traded at $0.774, with a market cap of 82.08M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.7501 and $0.7771. The current price is 3.2% above the day's low and 0.4% below its high.

Volume so far is 274.25K shares, below the average of 1.26M shares a day.

Over the past year Hyperfine has ranged from $0.74 to $1.94, and now sits 3% of the way up that range.

Hyperfine met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.09 per share against an estimate of -$0.0918.

The average analyst price target is $2.07, 168.0% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $2.07
Low
$1.62
Now
$0.774
High
$2.63

HYPR earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 12.1% on average.

  1. Q3 FY24: reported -$0.14 per share against an estimate of -$0.1428
  2. Q4 FY24: reported -$0.14 per share against an estimate of -$0.1377
  3. Q1 FY25: reported -$0.14 per share against an estimate of -$0.1199
  4. Q2 FY25: reported -$0.12 per share against an estimate of -$0.1224
  5. Q3 FY25: reported -$0.11 per share against an estimate of -$0.1071
  6. Q4 FY25: reported -$0.05 per share against an estimate of -$0.0816
  7. Q1 FY26: reported -$0.08 per share against an estimate of -$0.0952
  8. Q2 FY26: reported -$0.09 per share against an estimate of -$0.0918

HYPR news

  • Press releaseBusiness Wire

    Hyperfine Reports Record Preliminary Third Quarter Revenue of Approximately $6.0 Million & Reaffirms Full Year 2026 Revenue Outlook of Approximately $20 to $22 Million

  • Press releaseBusiness Wire

    Hyperfine, Inc. to Announce Third Quarter 2026 Financial Results on November 9, 2026

  • Press releaseBusiness Wire

    Hyperfine Expands Global Access to Portable Brain MRI Technology Across Key Gulf Cooperation Council Healthcare Markets

  • Press releaseBusiness Wire

    Hyperfine Announces Completion of Enrollment in the Contrast PMR Study to Support the Submission to Expand Indications for Use of the Swoop® System with Contrast Agents

  • Press releaseBusiness Wire

    Hyperfine, Inc. to Participate in Lake Street Capital Markets 10th Annual Best Ideas Growth Conference

  • Press releaseBusiness Wire

    Hyperfine Builds Momentum in Year One of Neurology Office Launch with NEURO PMR Publication and More Than 3,000 Scans

  • Press releaseBusiness Wire

    Hyperfine Announces FDA Clearance of the Next Optive AI™ Software, Further Enhancing Image Quality, Clinical Utility, and Ease of Use of the Swoop® System Across Care Settings

  • Press releaseBusiness Wire

    Hyperfine, Inc. Reports Second Quarter 2026 Financial Results

Similar companies

Companies in the same industry as Hyperfine

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.